Vivus, Inc. operates in the Pharmaceutical preparations sector. VIVUS, Inc. is a biopharmaceutical company. The Company is engaged in development and commercialization of therapeutic drugs for large underserved markets, including obesity and related morbidities, such as sleep apnea and diabetes and men's sexual health. As of December 31, 2010, it had one investigational drug candidate, QNEXA, which has been submitted for approval as a treatment for weight loss in the United States and the European Union. In the United States, it received a complete response letter for QNEXA in October 2010, which contained requests for additional information. As of December 31, 2010, it also had investigational drug candidates in various stages of clinical development for various indications related to obesity, erectile dysfunction and other diseases. On November 5, 2010, it sold certain rights and assets related to MUSE, transurethral alprostadil, for the treatment of erectile dysfunction to Meda AB. In our complete report available for purchase the company is compared to: Progenics Pharmaceuticals, Inc., InterMune, Inc. and Dendreon Corporation.